GlaxoSmithKline recently announced data from a phase III trial its oncology drug, Votrient (pazopanib). This trial evaluated the use of Votrient as maintenance therapy in women suffering from epithelial ovarian, fallopian tube or primary peritoneal cancer,

Glaxo Reports Votrient Data - Analyst Blog

NASDAQ

GlaxoSmithKline  recently announced data from a phase III trial (n = 940) evaluating its oncology drug, Votrient (pazopanib). The randomized, double-blind, placebo-controlled phase III trial evaluated the use of Votrient as maintenance therapy in women suffering from epithelial ovarian, fallopian tube or primary peritoneal cancer,

http://www.nasdaq.com/article/glaxo-reports-votrient-data-analyst-blog-cm250408


BY WORLD DRUG TRACKER
DR ANTHONY MELVIN CRASTO